source
- AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeuticsAbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…
- FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failureThe U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…